Macquarie notes foot traffic for around 100 of the US-based collection centres has eased after hitting a new peak mid November. In conjunction, coronavirus cases in the US have increased.
While the broker assumes a recovery in immunoglobulin growth and earnings for CSL Behring in FY22, plasma collection continues to present risks for the short term. Neutral rating. Target is $296.
Sector: Pharmaceuticals, Biotechnology & Life Sciences.
Target price is $296.00.Current Price is $293.80. Difference: $2.20 – (brackets indicate current price is over target). If CSL meets the Macquarie target it will return approximately 1% (excluding dividends, fees and charges – negative figures indicate an expected loss).
